Source: BioSpace

Glaukos: Glaukos Corporation Announces Second Quarter 2020 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2020.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Thomas W Burns's photo - President & CEO of Glaukos Corp

President & CEO

Thomas W Burns

CEO Approval Rating

88/100

Glaukos is an ophthalmic medical device firm that creates micro invasive glaucoma surgery options for patients. Read more